XML 33 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements (Details 3) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 28, 2013
Levitronix Medical
 
Changes in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3)  
Balance, beginning of the fiscal year $ 22,052
Payments (4,220)
Change in fair value 3,647
Balance, end of the fiscal year 21,479
DuraHeart II Acquisition
 
Changes in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3)  
Additions 18,800
Change in fair value 266
Balance, end of the fiscal year 19,066
Auction rate securities
 
Reconciliation of the beginning and ending balances for the assets measured as fair value using significant unobservable inputs (Level 3):  
Balance, beginning of the fiscal year 10,607
Settlements at par (2,200)
Unrealized gain on auction rate securities, included in other comprehensive income 553
Balance, end of the fiscal year 8,960
Auction rate securities | Short-term investments
 
Reconciliation of the beginning and ending balances for the assets measured as fair value using significant unobservable inputs (Level 3):  
Balance, end of the fiscal year (4,800)
Auction rate securities | Long-term investments
 
Reconciliation of the beginning and ending balances for the assets measured as fair value using significant unobservable inputs (Level 3):  
Balance, end of the fiscal year 4,160
Contingent Consideration
 
Changes in liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3)  
Balance, beginning of the fiscal year 22,052
Additions 18,800
Payments (4,220)
Change in fair value 3,913
Balance, end of the fiscal year $ 40,545